Overview

Dose-Ranging Efficacy and Safety Study of Topical Rapamycin Cream for Facial Angiofibroma Associated With Tuberous Sclerosis Complex

Status:
Recruiting

Trial end date:
2021-11-01

Target enrollment:

Participant gender:

Summary

The study aims to compare the safety and efficacy of two different strengths of Rapamycin cream, topical and placebo over 26 weeks in the treatment of facial angiofibroma (FA) associated with Tuberous Sclerosis Complex (TSC).

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Dermatology Specialties Limited Partnership

Treatments:

Everolimus
Sirolimus